NICHOLAS VELLEMA: Open Payments
NPI 1871961789 · WEST DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$795 in 46 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $963 · 2025 $795
Food & beverage: $795
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $207 |
| ABBVIE INC. | 16 | $158 |
| Otsuka America Pharmaceutical, Inc. | 3 | $78 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| PFIZER INC. | 2 | $43 |
| Neos Therapeutics, LP | 2 | $39 |
| Novo Nordisk Inc | 2 | $31 |
| Janssen Pharmaceuticals, Inc | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Biogen, Inc. | 1 | $24 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Auvelity, NURTEC ODT, Wegovy, SPRAVATO, COBENFY.
Industry payments across IA — which companies pay providers there.
